Home › Health Risks of an Inactive Lifestyle › NCT05147909
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity
Who can join
Ages 18 to 80 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: The randomized crossover trial will be performed in on otherwise healthy subjects without diabetes mellitus, chronic kidney disease (CKD), preexisting cardiovascular disease or treatment with any vasoactive agent that might alter cardiovascular responses to exercise. Exclusion Criteria: 1. history of cardiopulmonary disease or chronic kidney disease, 2. treatment with antihypertensive medications, 3. estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2, (4) diabetes mellitus or other systemic illness, (5) pregnancy, (6) hypersensitivity to sodium phosphate, (7) any history of substance abuse or current cigarette use, (8) any history of psychiatric illness, (9) history of active malignancy, (10) serum phosphorus \< 2.4 or \> 4.5 mg/dL.
About the study
Studies in mice demonstrated that dietary phosphate (Pi) loading that mimic the level of US adult consumption leads to reduced spontaneous locomotor activity, exercise capacity, and reduced resting metabolic rate when in normal mice by impairing skeletal muscle mitochondrial function and fat oxidation. However, relevance of this findings in humans remains unknown.
What is being tested
- Sodium Phosphate (dietary supplement)
- Sodium Chloride (dietary supplement)
Sponsor: University of Texas Southwestern Medical Center · Participants: 124 · Started: Sep 14, 2022
Contact the study team
- John Giacona, PA-C · Phone: 2146484403
Official record on ClinicalTrials.gov — NCT05147909
Locations in the U.S.
| Texas | University of Texas Southwestern, Dallas |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.